King Luther Capital Management Corp Has $7.35 Million Stock Position in Charles River Laboratories International, Inc. $CRL

King Luther Capital Management Corp lessened its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 10.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 46,980 shares of the medical research company’s stock after selling 5,220 shares during the quarter. King Luther Capital Management Corp’s holdings in Charles River Laboratories International were worth $7,350,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in CRL. Vanguard Group Inc. increased its stake in shares of Charles River Laboratories International by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 5,839,743 shares of the medical research company’s stock worth $913,686,000 after purchasing an additional 27,989 shares during the last quarter. Ariel Investments LLC raised its stake in Charles River Laboratories International by 28.6% in the second quarter. Ariel Investments LLC now owns 1,415,348 shares of the medical research company’s stock valued at $214,751,000 after buying an additional 314,572 shares during the period. Invesco Ltd. lifted its position in shares of Charles River Laboratories International by 11.6% in the second quarter. Invesco Ltd. now owns 1,237,143 shares of the medical research company’s stock valued at $187,712,000 after buying an additional 128,785 shares during the last quarter. Bank of America Corp DE increased its holdings in shares of Charles River Laboratories International by 29.2% during the 2nd quarter. Bank of America Corp DE now owns 1,026,013 shares of the medical research company’s stock worth $155,677,000 after acquiring an additional 232,020 shares during the last quarter. Finally, Sei Investments Co. increased its holdings in shares of Charles River Laboratories International by 5.9% during the 2nd quarter. Sei Investments Co. now owns 714,688 shares of the medical research company’s stock worth $108,440,000 after acquiring an additional 39,959 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have issued reports on CRL. Evercore raised their price objective on shares of Charles River Laboratories International from $250.00 to $260.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 13th. Bank of America upgraded shares of Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 price target on the stock in a research note on Monday, December 15th. Robert W. Baird set a $193.00 price objective on shares of Charles River Laboratories International in a report on Thursday. JPMorgan Chase & Co. increased their target price on shares of Charles River Laboratories International from $165.00 to $190.00 and gave the stock a “neutral” rating in a research report on Monday, December 15th. Finally, Wall Street Zen upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating in a research report on Saturday, February 7th. Ten research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $205.92.

Charles River Laboratories International Stock Performance

NYSE CRL opened at $163.66 on Friday. The firm’s 50 day simple moving average is $200.84 and its 200 day simple moving average is $179.33. The firm has a market capitalization of $8.06 billion, a price-to-earnings ratio of -55.29, a P/E/G ratio of 4.69 and a beta of 1.63. The company has a current ratio of 1.29, a quick ratio of 1.10 and a debt-to-equity ratio of 0.67. Charles River Laboratories International, Inc. has a 1 year low of $91.86 and a 1 year high of $228.88.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, February 18th. The medical research company reported $2.39 earnings per share for the quarter, topping the consensus estimate of $2.33 by $0.06. The firm had revenue of $994.23 million during the quarter, compared to analysts’ expectations of $986.98 million. Charles River Laboratories International had a positive return on equity of 15.60% and a negative net margin of 3.59%.The company’s quarterly revenue was down .8% on a year-over-year basis. During the same period in the prior year, the company earned $2.66 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. As a group, research analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Charles River Laboratories International News Summary

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Q4 results beat consensus on both EPS and revenue, with management providing a slide deck and call that highlighted margin expansion versus prior quarters — a near‑term catalyst supporting the move higher. Q4 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Management set FY‑2026 EPS guidance roughly in line with or slightly above Street expectations and reiterated confidence in improving demand for drug‑development services — this guidance reduces near‑term forecast uncertainty. Reuters: Charles River forecasts upbeat 2026 profit
• Positive Sentiment: Company announced executive appointments and emphasized cost‑savings, acquisitions and a new CEO strategy that management says will drive ~up to 9% EPS growth and margin expansion — a constructive strategic signal for investors. Executive Appointments
• Neutral Sentiment: Full earnings call transcript and slide deck released; provides detail on segment trends, backlog and timing of biotech demand recovery — useful for adjusting model assumptions but not an immediate directional trigger. Earnings Call Transcript
• Negative Sentiment: Underlying organic growth softened (revenue down ~0.8% YoY) and some coverage flagged flat sales and margin pressures in parts of the business — risks that could cap multiple expansion until growth inflects. Deep Dive: Flat Sales and Margin Pressures
• Negative Sentiment: Several analysts noted the stock dipped intraday last week despite the beat due to concerns around slowing organic demand and mixed segment performance — continued execution risk remains. Stock Down Despite Beat

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.